Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Drug Name | RPTR-147 |
Trade Name | |
Synonyms | RPTR147|RPTR 147|PRIME IL-15 |
Drug Descriptions |
RPTR-147 is a cell therapy that consists of autologous T-lymphocytes primed with PRAME, NYESO-1, SSX2, Survivin, and WT1 tumor associated antigens (TAAs), followed by IL15-Fc nanogel loading, which potentially induces immune response against tumor cells expressing TAAs (Journal for ImmunoTherapy of Cancer 2020;8; Abs nr: 801). |
DrugClasses | |
CAS Registry Number | NA |
NCIT ID | NA |
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|---|---|---|
Pembrolizumab + RPTR-147 | Pembrolizumab RPTR-147 | 0 | 1 |
RPTR-147 | RPTR-147 | 0 | 1 |